Discovery of novel dual functional agent as PPARγ agonist and 11β-HSD1 inhibitor for the treatment of diabetes

被引：26

作者：

Ye, Yang-liang ^{[2
]}

Zhou, Zhou ^{[2
]}

Zou, Han-jun ^{[2
]}

Shen, Yu ^{[2
]}

Xu, Ti-fei ^{[2
]}

Tang, Jing ^{[2
]}

Yin, Hua-zhong ^{[1
]}

Chen, Min-li ^{[1
]}

Leng, Ying ^{[2
]}

Shen, Jian-hua ^{[2
]}

机构：

[1] Zhejiang Chinese Med Univ, Hangzhou 310053, Zhejiang, Peoples R China

[2] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2009年 / 17卷 / 15期

基金：

中国国家自然科学基金;

关键词：

Type; 2; diabetes; PPAR gamma agonists; 11; beta-HSD1; inhibitors; Molecular modeling; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; ACTIVATED-RECEPTOR-GAMMA; ANTIDIABETIC THIAZOLIDINEDIONE; 3T3-L1; ADIPOGENESIS; INSULIN; POTENT; OBESITY; DESIGN; GLUCOCORTICOIDS; DIFFERENTIATION;

D O I：

10.1016/j.bmc.2009.05.082

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

PPAR gamma and 11 beta-HSD1 are attractive therapeutic targets for type 2 diabetes. However, PPAR gamma agonists induce adipogenesis, which causes the side effect of weight gain, whereas 11 beta-HSD1 inhibitors prevent adipogenesis and may be beneficial for the treatment of obesity in diabetic patients. For the first time, we designed, synthesized a series of alpha-aryloxy-alpha-methylhydrocinnamic acids as dual functional agents which activate PPAR gamma and inhibit 11 beta-HSD1 simultaneously. The compound 11e exhibited the most potent inhibitory activity compared to that of the lead compound 2, with PPAR gamma (EC50 = 6.76 mu M) and 11 beta-HSD1 (IC50 = 0.76 mu M) in vitro. Molecular modeling study for compound 11e was also presented. Compound 11e showed excellent efficacy for lowering glucose, triglycerides, body fat, in well established mice and rats models of diabetes and obesity and had a favorable ADME profile. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：5722 / 5732

页数：11

共 40 条

[11] Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO
[12] 2-6
[13] Rapid and direct measurement of free concentrations of highly protein-bound fluoxetine and its metabolite norfluoxetine in plasma
Guo, B
Li, C
Wang, GJ
Chen, LS
[J]. RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2006, 20 (01) : 39 - 47
[14] 2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11β-hydroxysteriod dehydrogenase type 1
Jean, David J. St., Jr.
Yuan, Chester
Bercot, Eric A.
Cupples, Rod
Chen, Michelle
Fretland, Jenne
Hale, Clarence
Hungate, Randall W.
Komorowski, Renee
Veniant, Murielle
Wang, Minghan
Zhang, Xiping
Fotsch, Christopher
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (03) : 429 - 432
[15] Diabetes: New challenges for the control of disease globalisation
Kargul, J
Laurent, GJ
[J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (5-6) : 685 - 686
[16] Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity
Kershaw, EE
Morton, NM
Dhillon, H
Ramage, L
Seckl, JR
Flier, JS
[J]. DIABETES, 2005, 54 (04) : 1023 - 1031
[17] Differential modulation of 3T3-L1 adipogenesis mediated by 11β-hydroxysteroid dehydrogenase-1 levels
Kim, Jaime
Temple, Karla A.
Jones, Sara A.
Meredith, Kimberly N.
Basko, Juliana L.
Brady, Matthew J.
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (15) : 11038 - 11046
[18] A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones
King, AB
[J]. DIABETES CARE, 2000, 23 (04) : 557 - 557
[19] KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393
[20] AN ANTIDIABETIC THIAZOLIDINEDIONE IS A HIGH-AFFINITY LIGAND FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA(PPAR-GAMMA)
LEHMANN, JM
MOORE, LB
SMITHOLIVER, TA
WILKISON, WO
WILLSON, TM
KLIEWER, SA
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (22) : 12953 - 12956

← 1 2 3 4 →